期刊档案 · Medicine-Biochemistry (medical)

Advances in Biomarker Sciences and Technology

ISSN 2543-1064 · KeAi Communications Co. Ltd. · China

Advances in Biomarker Sciences and Technology 完全开放获取,APC 约 700 美元,投稿社区反馈审稿约 20 周,2025 年发文 42 篇,Scopus 收录。

影响因子—暂无公布值
中科院分区—未被分区表收录
审稿周期约 20 周投稿社区平均反馈
版面费700 USD完全开放获取
录用比例—暂无反馈
年发文量42 篇2025 年 · OpenAlex 统计

研究范围

研究范围与定位

Advances in Biomarker Sciences and Technology 由 KeAi Communications Co. Ltd. 出版。按 OpenAlex 近年发文统计,该刊主要发表 MicroRNA in disease regulation、Gut microbiota and health、Essential Oils and Antimicrobial Activity 等主题的论文,这 3 个主题约占 20.8%。(根据 OpenAlex 主题统计与中科院分区数据生成)

Advances in Biomarker Sciences and Technology (ABST) is a rigorously peer-reviewed, fully open access journal that aims to encompass all aspects of biomarker research, from biomarker development to its applications, clinical diagnosis and treatment to molecular epidemiology and toxicology; from precision medicine to drug development, and from nanotechnology to bioinformatics. ABST focuses on building upon the next generation of biomarkers to accelerate communication of the latest advances in their identification as well as applications. We strive to achieve this objective by providing a high-quality forum for the publication of biomarker-related investigations, including (but not limited to) general research articles elucidating topics in novel technologies, study designs or mathematical models, invited and selected reviews, short communications and editorials. Editorial Board

摘自期刊官网 Aims & Scope

研究方向(LetPub):Medicine-Biochemistry (medical)

主编 Luoping Zhang Division出版商官网

编委会国家分布:中国大陆 25 位(约 52%);主要国家 中国 25、美国 11、中国香港 2、英国 2、意大利 2(共 48 位编委标注了国家) 编委会 ↗出版商官网 ·

主要研究主题 OpenAlex 近年发文统计,占比为近似值

  1. MicroRNA in disease regulationBiochemistry, Genetics and Molecular Biology8.3%
  2. Gut microbiota and healthBiochemistry, Genetics and Molecular Biology6.3%
  3. Essential Oils and Antimicrobial ActivityAgricultural and Biological Sciences6.3%
  4. Cancer-related molecular mechanisms researchBiochemistry, Genetics and Molecular Biology6.3%
  5. COVID-19 Clinical Research StudiesMedicine5.2%
  6. Computational Drug Discovery MethodsComputer Science4.2%
  7. Liver Disease Diagnosis and TreatmentMedicine4.2%
  8. Metabolomics and Mass Spectrometry StudiesBiochemistry, Genetics and Molecular Biology4.2%

分区与收录

学科分区与数据库收录

中科院期刊分区表

期刊分区表( 2025年3月升级版)未收录

该期刊未被此版本分区表收录。

《新锐期刊分区表》( 2026年3月发布)未收录

该期刊未被此版本分区表收录。

期刊分区表( 2023年12月旧的升级版)未收录

该期刊未被此版本分区表收录。

数据库收录

ScopusDOAJLetPub

国际期刊预警名单:各版本均未列入LetPub

不同版本、大类与小类分别展示,不将不同评价口径合并为一个分区值;投稿与考核前请确认所在机构采用的版本。

指标

影响力指标与发文规模

影响力指标

CiteScore 2026-06
3.1LetPub ·
CiteScore(出版商公布)
3.1出版商官网 ·
SJR 2026-06
0.34LetPub ·
SNIP 2026-06
0.5LetPub ·
h-index
13OpenAlex ·
i10-index
17OpenAlex ·
两年平均被引
2.26OpenAlex ·
Gold OA 文章占比
0%LetPub ·

逐年发文量 OpenAlex 统计 · 累计 134 篇 · 当年数据不完整

年份发文量其中 OA被引
2026404026
20254242107
20242626111
2023131345
20224475
20212219

不同来源的统计口径与观测时间不同,页面保留各来源原值;“出版商公布”为期刊官网自述数据。

审稿与录用

审稿周期与录用情况

平均审稿速度(社区反馈)
20 WeeksLetPub ·
投稿到发表(期刊自报)
约 20 周DOAJ ·
评审方式
单盲同行评审DOAJ

社区反馈来自投稿者样本,置信度 0.5,不代表期刊承诺;“出版商公布”的时间节点定义以官网为准。

费用与开放获取

版面费与开放获取政策

完全开放获取DOAJ

所有文章开放获取,通常向作者收取文章处理费(APC)。

来源文章处理费费用减免许可证观测时间
DOAJUSD 700有CC BY、CC BY-NC-ND
OpenAlexUSD 700——
LetPubUSD 700有—
出版商官网USD 700——

费用以期刊官网为准;不同来源的观测时间可能不同,页面保留各来源原值,不做平均。

投稿要求

文章类型与投稿政策(官网)

投稿准备要点4 项,摘自作者指南
摘要
≤ 250 词
关键词
≥ 3 个
参考文献格式
AMA 格式
Highlights(研究亮点)
可选
出版商官网 · 模型提取,逐项与原文核对
接收的文章类型10 种
  1. articleArticle, Review, Short Communication, Microarticle, Opinion, Practice Guidelines, Technical Note, Original Software Publication, Editorial, Correspondence未说明篇幅
  2. correspondenceArticle, Review, Short Communication, Microarticle, Opinion, Practice Guidelines, Technical Note, Original Software Publication, Editorial, Correspondence未说明篇幅
  3. editorialArticle, Review, Short Communication, Microarticle, Opinion, Practice Guidelines, Technical Note, Original Software Publication, Editorial, Correspondence未说明篇幅
  4. microarticleArticle, Review, Short Communication, Microarticle, Opinion, Practice Guidelines, Technical Note, Original Software Publication, Editorial, Correspondence未说明篇幅
  5. opinionArticle, Review, Short Communication, Microarticle, Opinion, Practice Guidelines, Technical Note, Original Software Publication, Editorial, Correspondence未说明篇幅
  6. original software publicationArticle, Review, Short Communication, Microarticle, Opinion, Practice Guidelines, Technical Note, Original Software Publication, Editorial, Correspondence未说明篇幅
  7. practice guidelinesArticle, Review, Short Communication, Microarticle, Opinion, Practice Guidelines, Technical Note, Original Software Publication, Editorial, Correspondence未说明篇幅
  8. reviewArticle, Review, Short Communication, Microarticle, Opinion, Practice Guidelines, Technical Note, Original Software Publication, Editorial, Correspondence未说明篇幅
  9. short communicationArticle, Review, Short Communication, Microarticle, Opinion, Practice Guidelines, Technical Note, Original Software Publication, Editorial, Correspondence未说明篇幅
  10. technical noteArticle, Review, Short Communication, Microarticle, Opinion, Practice Guidelines, Technical Note, Original Software Publication, Editorial, Correspondence未说明篇幅
出版商官网
官网政策摘录AI 使用、作者资格、利益冲突、许可与版权、开放获取、同行评审、查重、预印本
AI 使用 Declaration of generative AI use

作者在投稿时必须声明在稿件准备过程中使用生成式人工智能工具的情况;AI 工具只能在人类监督和控制下使用,绝不能替代人类的批判性思维、专业知识和评估。 模型中文摘要

Authors must declare the use of generative AI tools in the manuscript preparation process upon submission of the paper. Generative AI and AI-assisted technologies (“AI tools”) have been rapidly adopted in research and scholarly publishing, offering significant benefits while requiring clear standards for responsible and transparent use. Authors preparing a manuscript for this journal may use AI to…

原文 ↗出版商官网 ·
作者资格 Authorship

所有作者都应对研究的设计与构思、数据获取或分析解释、文章撰写或关键性修改以及最终版本的批准做出实质性贡献,并对工作的所有方面负责;作者须指定一名通讯作者与期刊沟通。 模型中文摘要

All authors should have made substantial contributions to all of the following: The conception and design of the study, or acquisition of data, or analysis and interpretation of dataDrafting the article or revising it critically for important intellectual content.Final approval of the version to be submitted. All authors are accountable for all aspects of the work, to ensure that questions related…

原文 ↗出版商官网 ·
利益冲突 Declaration of competing interests

所有作者必须披露可能不当影响或偏颇其工作的与他人或组织的财务和个人关系,包括雇佣、咨询、持股、酬金、付费专家证言、专利申请或授权、资助以及作为期刊编辑或顾问委员会成员的隶属关系等潜在竞争利益,并须始终填写声明工具。 模型中文摘要

All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence or bias their work. Examples of potential competing interests include: EmploymentConsultanciesStock ownershipHonorariaPaid expert testimonyPatent applications or registrationsGrants or any other fundingAffiliation with the journal as an Editor or Advisory Board…

原文 ↗出版商官网 ·
许可与版权 Creative Commons Attribution (CC BY)

该许可允许用户分发和复制文章、制作摘录、摘要及其他改编或衍生作品、收入合集以及对文章进行文本或数据挖掘,即使用于商业目的也可,但前提是须恰当署名、附许可链接、注明修改且不得损害作者名誉。 模型中文摘要

Allows users to: distribute and copy the article; create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation); include in a collective work (such as an anthology); and text or data mine the article. These uses are permitted even for commercial purposes, provided the user: gives appropriate credit to the author(s) (with a lin…

原文 ↗出版商官网 ·
开放获取 KeAi Guide for authors: Open Access

这是一本开放获取期刊,所有文章将立即且永久免费供所有人阅读和下载;为提供开放获取,作者或其资助者或机构需支付开放获取费用(文章出版费 APC),第三方允许的再使用由 Creative Commons 许可证定义。 模型中文摘要

This is an open access journal: all articles will be immediately and permanently free for everyone to read and download. To provide open access, this journal has an open access fee (also known as an article publishing charge APC) which needs to be paid by the authors or on their behalf e.g. by their research funder or institution. Permitted third party (re)use is defined by the following Creative …

原文 ↗出版商官网 ·
同行评审 Peer review

该期刊采用单盲同行评审流程,投稿先由编辑评估是否适合发表,适合的稿件通常送至少两名审稿人进行独立专家评估,接受或拒绝的决定由编辑作出且为最终决定。 模型中文摘要

This journal follows a single anonymized review process. Your submission will initially be assessed by our editors to determine suitability for publication in this journal. If your submission is deemed suitable, it will typically be sent to a minimum of two reviewers for an independent expert assessment of the scientific quality. The decision as to whether your article is accepted or rejected will…

原文 ↗出版商官网 ·
查重

提交至 KeAi 期刊的稿件会在编辑系统内自动使用 iThenticate 的 CrossCheck 进行筛查,以检测包括重叠和相似文本在内的抄袭问题。 模型中文摘要

Submissions to KeAi journals are automatically screened using iThenticate's CrossCheck within the editorial system to detect plagiarism issues including instances of overlapping and similar text in submitted manuscripts.

原文 ↗出版商官网 ·
预印本 Preprint sharing

作者可按照 Elsevier 的文章共享政策分享预印本,例如在预印本服务器上分享预印本不会被视为提前发表。 模型中文摘要

Authors may share preprints in line with Elsevier's article sharing policy. Sharing preprints, such as on a preprint server, will not count as prior publication. We advise you to read our policy on multiple, redundant or concurrent publication.

原文 ↗出版商官网 ·

摘录来自期刊官网页面,仅保留原文片段;“模型摘要”由 Workers AI 生成并经原文校验,以官网为准。

基本信息

出版信息与官方入口

出版商
KeAi Communications Co. Ltd.
出版国家或地区
China
出版语言
English
ISSN
2543-1064
官方链接

常见问题

关于 Advances in Biomarker Sciences and Technology 的常见问题

Advances in Biomarker Sciences and Technology 的审稿周期多长?

投稿社区反馈的平均审稿速度为约 20 周。文章统计只含被录用的稿件,出版商数据口径以官网为准,社区反馈来自投稿者样本,均不代表期刊承诺。

Advances in Biomarker Sciences and Technology 的投稿格式要求是什么?

据期刊作者指南:摘要:≤ 250 词;关键词:≥ 3 个;参考文献格式:AMA 格式;Highlights:可选。以上由模型从作者指南提取并逐项与原文核对,投稿前请以官网最新版本为准。

Advances in Biomarker Sciences and Technology 的编委会里有中国学者吗?

期刊官网编委会页面上标注了国家的 48 位编委中,中国大陆 25 位(约 52%);人数最多的国家是 中国(25 位)、美国(11 位)、中国香港(2 位)。统计按编委会页面列出的机构国家计,仅供参考。

Advances in Biomarker Sciences and Technology 被哪些数据库收录?

据 LetPub 与 DOAJ 记录,Advances in Biomarker Sciences and Technology 被 Scopus、DOAJ 收录。

Advances in Biomarker Sciences and Technology 是开放获取期刊吗?版面费多少?

Advances in Biomarker Sciences and Technology 为完全开放获取。APC 约 700 美元。

来源与更新

本页事实来自 LetPub、OpenAlex、DOAJ、出版商官网;每个数字旁标注来源与观测日期,冲突数据保留各来源原值。LetPub 原始详情页:查看 ↗(2026-08-25 归档)。最近更新:。